Literature DB >> 19029997

Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials?

Ruchika Gutt1, Stanley L Liauw, Ralph R Weichselbaum.   

Abstract

Surgical resection is the most effective means of controlling nonmetastatic pancreatic cancer, but recurrence rates are high even after complete resection. For several types of tumor of the gastrointestinal tract, combined modality therapy that includes radiation therapy has been shown to reduce the recurrence rate and improve disease-free survival. The use of adjuvant radiotherapy for pancreatic cancer, however, is controversial. Results of the few randomized trials of adjuvant radiotherapy for pancreatic cancer are conflicting. In addition, as pancreatic cancer is associated with high rates of distant recurrence, the additional benefit provided by local therapy has been perceived as questionable. This article reviews the studies--prospective and retrospective--of adjuvant radiotherapy for pancreatic cancer and the issues surrounding the use of this strategy.

Entities:  

Mesh:

Year:  2008        PMID: 19029997     DOI: 10.1038/ncpgasthep1301

Source DB:  PubMed          Journal:  Nat Clin Pract Gastroenterol Hepatol        ISSN: 1743-4378


  46 in total

1.  One thousand consecutive pancreaticoduodenectomies.

Authors:  John L Cameron; Taylor S Riall; JoAnn Coleman; Kenneth A Belcher
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

Review 3.  Adjuvant treatment for resectable pancreatic cancer.

Authors:  Yu Jo Chua; David Cunningham
Journal:  J Clin Oncol       Date:  2005-07-10       Impact factor: 44.544

4.  Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.

Authors:  Axel Richter; Marco Niedergethmann; Jörg W Sturm; Dietmar Lorenz; Stefan Post; Michael Trede
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

5.  Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome.

Authors:  Michael T Milano; Steven J Chmura; Michael C Garofalo; Carla Rash; John C Roeske; Phillip P Connell; Oh-Hoon Kwon; Ashesh B Jani; Ruth Heimann
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

6.  Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil.

Authors:  M L Foo; L L Gunderson; D M Nagorney; D C McLlrath; J A van Heerden; J S Robinow; L K Kvols; G R Garton; J A Martenson; S S Cha
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-06-15       Impact factor: 7.038

7.  Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA): employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity.

Authors:  Jerome C Landry; Gary Y Yang; Joseph Y Ting; Charles A Staley; William Torres; Natia Esiashvili; Lawrence W Davis
Journal:  Med Dosim       Date:  2002       Impact factor: 1.482

8.  Pancreatic and periampullary carcinoma. Experience with 200 patients over a 12 year period.

Authors:  R J Piorkowski; S W Blievernicht; W Lawrence; J Madariaga; J S Horsley; J P Neifeld; J J Terz
Journal:  Am J Surg       Date:  1982-02       Impact factor: 2.565

9.  Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head.

Authors:  C H Crane; J A Antolak; I I Rosen; K M Forster; D B Evans; N A Janjan; C Charnsangavej; P W Pisters; R Lenzi; M A Papagikos; R A Wolff
Journal:  Int J Gastrointest Cancer       Date:  2001

10.  Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005).

Authors:  Michele M Corsini; Robert C Miller; Michael G Haddock; John H Donohue; Michael B Farnell; David M Nagorney; Aminah Jatoi; Robert R McWilliams; George P Kim; Sumita Bhatia; Matthew J Iott; Leonard L Gunderson
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

View more
  4 in total

1.  Accomplishments in 2008 in the management of localized pancreatic cancer.

Authors:  Eileen M O'Reilly; Manfred P Lutz; Peter Neuhaus
Journal:  Gastrointest Cancer Res       Date:  2009-09

2.  A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database.

Authors:  May Piperdi; Theodore P McDade; Joon K Shim; Bilal Piperdi; Sidney P Kadish; Mary E Sullivan; Giles F Whalen; Jennifer F Tseng
Journal:  HPB (Oxford)       Date:  2010-04       Impact factor: 3.647

Review 3.  Pancreatic cancer: pathobiology, treatment options, and drug delivery.

Authors:  Jing Li; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-03-03       Impact factor: 4.009

Review 4.  Adjuvant and neoadjuvant treatment in pancreatic cancer.

Authors:  Marta Herreros-Villanueva; Elizabeth Hijona; Angel Cosme; Luis Bujanda
Journal:  World J Gastroenterol       Date:  2012-04-14       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.